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Abstract
Background: Conventional treatments for breast cancer involve surgery followed by radiation and hormonal
therapy and/or chemotherapy. Some of these treatments have toxic side effects. Because drugs used in
chemotherapy affect both cancer and normal cells to varying degrees, researchers are currently developing targeted
drugs that only attack cancer cells without affecting normal cells. One approach to this is to found compounds that
are more selective and specific, destroying only tumour cells and prevent metastases without harming normal cells.
For thousands of years, medicinal mushrooms have been used because of their healing properties. Maitake (Grifola
frondosa) is one of the most promising edible and medicinal mushroom, acting promoting the immune system
against the tumorigenesis process.
Methods: In the in vitro studies, we measured and compared the effect of Maitake Pro4X or Chemotherapy on
LM3 Breast Tumour Cells death. Increased concentrations and different time of treatments were employed. In the in
vivo studies, we employed breast tumour bearing female BALBc mice 6-8 weeks old, to assayed the effect of
Maitake Pro4X with or without chemotherapy measuring the tumour volume, mortality, relative survival and size of
tumour necrosis area after treatment.
Results: After 5 weeks of treatment in tumour-bearing BALBc mice, we observed that Maitake Pro4X significantly
increased the overall survival of animals and reduced the malignancy of breast tumours. We also found that Maitake
Pro4X, as chemotherapy, induce cell-death in a dose and time dependent form.
Conclusion: The beneficial effects of Maitake D-Fraction Pro4X, if supported by further evidence could be useful
for the treatment of cancer patients to reduce the adverse effects of the conventional chemotherapy treatment.
Keywords: Breast cancer; Maitake Pro4X; Chemotherapy; Cancer
treatment
Introduction
Breast cancer is the second most common cancer in the world
today. The approach to treating breast cancer should involve a holistic
view of the patient, which requires a multidisciplinary treatment team
[1]. When cancer becomes metastatic, the goal of treatment is
palliative, aiming to prolong survival and to improve the patient’s
quality of life. Although the average survival rate is low overall, some
women with breast cancer may survive longer [2]. Treatment is usually
divided into standard chemotherapy and targeted therapy [3].
Chemotherapy is used for several purposes: to cure cancer, to
prevent the spread of cancer, to remove metastatic cells, and to reduce
symptoms to improve patients’ quality of life when a cure is not
possible [4]. Chemotherapy works by taking advantage of the increased
sensitivity to treatment of rapidly dividing cells; accordingly, it affects
not only cancer cells but also normal actively dividing cells, including
cells of the bone marrow, the digestive tract and hair follicles [5]. This
lack of specificity explains some of the common side effects such as
myelosuppression, mucositis and alopecia [6-8]. In addition to its low
specificity, chemotherapy is also limited as a treatment method due to
development of drug resistance by cancer cells. Doxorubicin, isolated
from a mutant Streptomyces peucetius, is an antibiotic in the
anthracycline family [9,10]. Doxorubicin is a cytotoxic chemotherapy
used to treat various cancers, including breast cancer, and it has a
broader and more efficient spectrum against tumours than its
predecessor, adriamycin. Doxorubicin inhibits tumour cell
proliferation by mechanisms that lead to DNA disruption [4,9]. Free
radical formation is also involved in DNA breakage and in cellular
lipid peroxidation, cell membrane disruption and protein kinase C
(PKC) activation, which induces apoptosis [11]. Like any
chemotherapy drug, doxorubicin has adverse effects, including a dose-
dependent cardiotoxic effect [9,12,13]. This toxicity is related to the
release of free radicals, which are responsible for oxidative stress,
leading to lipid peroxidation, protein degradation and cell membrane
damage by proteins, carbohydrates and DNA radicals, among other
adverse effects [14]. Cyclophosphamide is an alkylating agent in the
oxazaphosphorine group that has cytotoxic and immunosuppressive
activities [15,16]. It’s not only inhibits tumour cell multiplication but
also may act on blood cells, producing adverse effects. Alkylating
agents are thought to exert their immunosuppressive activity by
inhibiting nuclear DNA replication. A hydrogen atom is replaced by an
alkyl group, preferably at the N7 nitrogen of guanine, thus blocking
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DNA replication and transcription and leading to cell death [4,16].
Cyclophosphamide is a carcinogen that can cause secondary tumours
[17]. It has been shown to cause genetic mutations in somatic cells;
chromosomal aberrations, micronucleus formation and sister
chromatids exchange have also been observed [17]. The adverse effects
of cyclophosphamide are more frequent with prolonged treatment;
however, most of these effects are reversible if detected early.
In Asia, mushrooms are traditionally consumed for their nutritional
and medicinal properties, which were described as early as 2,700 B.C.
[18]. It is believed that only 10% of the estimated 140,000 species of
fungi on Earth have been identified. It is further estimated that only
5% of these species have known pharmacological properties [19]. The
production of biologically active metabolites by fungi represents a very
broad and promising field of study, which, until now, has received little
attention. Among the metabolites produced by fungi are antifungal,
antimicrobial, antiviral, and cytostatic agents and enzymes that
regulate growth [20,21]. Maitake is an edible and medicinal
mushroom; its extracts possess β-glucans with different degrees of
purification and have antitumor properties [22]. β-glucans in
mushrooms have a central straight chain of D-glucose moieties linked
together by β-1,3 glucans and with side branches of β-1,6 glucans of
various sizes. The β-glucans exert effects on the immune system,
stimulating phagocytic activity by activating leukocytes and inducing
the production of various cytokines, which could be responsible for
their antitumour activity [23,24]. The oral administration of extracts
derived from β-glucans of the medicinal mushroom Grifola frondosa
(Maitake) has been shown to stimulate haematopoiesis and immune
cells recovery post-paclitaxel treatment in animal models [25]. β-
glucans act on a variety of receptors in the immune system,
particularly on CR3 and Dectin-1, thereby triggering a broad spectrum
of immune responses [26]. β-glucans target immune cells, including
macrophages, neutrophils, monocytes, natural killer (NK) cells and
dendritic cells [26]. The immunomodulatory functions induced by β-
glucans involve innate and adaptive immune responses. However, the
exact mechanisms of immune system activation mediated by β-glucans
remain unknown.
In the present work, we studied the effects of Maitake D-Fraction
Pro4X in the treatment of mammary carcinogenesis in BALBc mice.
Today, given the limitations of conventional therapies to reduce
mortality from cancer, many efforts have focused on preventing
carcinogenesis. In this context, the use of immunopotentiators,
immune initiators or biological response modifiers (BRMs) that are
capable of stimulating the immune cells that can identify tumour cells
as foreign, eliminate and prevent carcinogenesis has gained
prominence [11]. β-glucans are BRMs that, unlike conventional
chemotherapeutic, activate or reinforce the host immune system,
helping to kill tumour cells or inhibit tumour growth. Maitake
fractions can fight cancer by slowing or stopping tumour growth and
by preventing metastasis [27]. These fractions can also decrease the
side effects of chemotherapy, including hair loss, pain and nausea,
while enhancing their benefits [28]. The ability to avoid chemotherapy
side effects would represent a breakthrough in the fight against cancer,
as it would improve patients’ quality of life and increase patient
survival. It has been demonstrate that cancer patients receiving
chemotherapy combined with Maitake showed improvements in some
of the adverse effects of chemotherapy, including hair loss, nausea,
vomiting, weight loss and leukopaenia. Maitake treatment was also
found to reduce patients’ pain [28]. One goal of the present work was
to compare the cytolytic effect in murine mammary tumour LM3 cells
in culture induced by Maitake Pro4x alone or in combination with
chemotherapeutic drugs (doxorubicin and cyclophosphamide) at
increased concentrations and at different times of treatment. The
second aim of this work was to evaluate the effect of Maitake Pro4X on
breast cancer treatment in mouse models, alone or in combination
with chemotherapy, and to determine whether there is or not an
adjuvant effect between both treatments.
Materials and Methods
Maitake D-Fraction Pro4X
Maitake D-Fraction Pro4X (Mushroom Wisdom Inc., N.J., USA) is
an ethanol extract from the medicinal mushroom, Grifola frondosa,
obtained under standard procedures performed by Mushroom
Wisdom, Inc. Maitake D-Fraction Pro4X contains 100 mg/ml of D-
Fraction, representing a 30% of active proteoglycan.
LM3 cell cultures
Tumourigenic LM3 cell line from metastatic mammary
adenocarcinoma derived from BALBc mice were used in the in vitro
studies. These murine cells lacked progesterone receptor (PR) and
estrogen receptor (ER) expression [29]. The LM3 cells were kindly
provided by Dr. Elisa Bal from Roffo Hospital, Buenos Aires-
Argentina. The cells were maintained with Minimum Essential
Medium (MEM) (GIBCO) supplemented with 10% foetal bovine
serum (FBS) at 37°C in a controlled atmosphere at 5% CO2/air and
saturated humidity.
Animal models
Female 6-8-week-old BALBc mice were inbred at the Institute of
Biomedical Research from Catholic University (UCA) Buenos Aires,
Argentina. They were kept in special boxes with a controlled
atmosphere and HEPA-filtered air at a controlled temperature of 22°C
and with a 12-hour light-dark cycle. The animals were fed with special
diet, and water was available ad libitum. We declare that all procedures
performed in animal models were previously approved by the Ethical
Committee of the Institute of Biomedical Research from the Medicine
Faculty-UCA-Buenos Aires, Argentina.
The effect of Maitake and/or chemotherapy on LM3 breast
tumour cell death
LM3 cultured cells were treat with increase concentrations of
Maitake Pro4X (0, 36, 91, 183, 267 and 734 μg/ml) and the experiment
were performed by duplicate. LM3 cells were also treated with or
without increase concentrations of Doxorubicine+Cyclophosphamide
(0, 5, 10, 15, 20 and 40 μM and 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM,
respectively). The effects on cell viability were evaluated at 24, 48 and
72 hours of treatment.
Determination of cell death
LM3 cell death was determined at 24, 48 and 72 hours of treatment
according to the method trypan blue exclusion test of cell viability/
death described in the literature [30].
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In vivo experimental design and treatment
The in vivo study included 30 female BALBc mice that were divided
into 3 groups of 10 mice each: Group 1, Group 2 and Group 3. In all
three groups, the tumourigenic process was induced by the
intraperitoneal injection with approximately 4 × 105 LM3 murine
breast tumour cells. Over the next 23 days, the mice were regularly
checked. Starting on the 24th day, and for 35 days, the mice of Group 1
received 80 mg/kg of cyclophosphamide+4 mg/kg doxorubicin weekly
by oral administration. The mice of group 2 were given orally 5 mg/kg
of Maitake Pro4X daily. The animals in group 3 received combined
treatment, chemotherapy (cyclophosphamide+doxorubicin) weekly+5
mg/kg of Maitake Pro4X daily (Figure 1). During the treatment period,
the tumour size was weekly measured.
Figure 1: Schematic of the experimental design. This figure
graphically shows the procedure that was followed in this project.
15 BALBc female mice were transplanted with LM3 tumoral cells to
induce breast tumourigenesis. After 3 weeks, treatment procedures
were performed for 5 weeks, mice were divided into three groups,
Group 1: Chemotherapy, Group 2: Chemotherapy+Maitake Pro4X
and Group 3: Maitake Pro4X, employing chemotherapy (4 mg/kg
doxorubicin+80 mg/kg cyclophosphamide) or Maitake Pro4X (5.00
mg/kg) either alone or in combination.
Tumor breast examination
Animals were checked weekly by visual examination and by
palpation of the abdominal-inguinal area to note the tumour
appearance. Progressively growing masses with a mean diameter >9
mm (0.90 cm) were regarded as tumour. The tumours were measured
with a digital calliper in two perpendicular diameters, and the volume
was calculated as (X2.Y)/2, where X and Y represent the smallest and
largest diameters, respectively.
Statistics analysis
The effect of treatment was tested by analysis of variance (ANOVA)
[31]. Differences among of means were assessed using Student’s t-tests.
Experiments were repeated by triplicate. Variability was expressed as
the standard error of the mean (SEM). Differences were considered
significant at p<0.05.
Results
Effect of Maitake Pro4X alone or in combination with
chemotherapy on mammary tumourigenesis
Similar tumour growth curves were observed in the treatment of
breast tumorigenesis with Maitake Pro4X alone or in combination with
chemotherapy (Figure 2A). At the beginning of treatment, the average
tumour size was 0.94 ± 0.21 cm in the group treated with
chemotherapy alone; 0.97 ± 0.22 cm (p=0.41) in the combined group
chemotherapy+Maitake and 0.87 ± 0.15 cm (p=0.29) in the group of
mice treated with Maitake Pro4X alone (Figure 2A). No significant
differences (p>0.05) were found in the tumour sizes at day 8th or 15th
of treatment in any experimental group. Furthermore, at the end of the
treatment (22 days of tumorigenesis), no significant differences (p>0.5)
were found in the size of tumour in any group (1.23 ± 0.42 cm 1.34 ±
0.15 cm or 1.16 ± 0.44 cm in chemotherapy group; in combined
treatment group and in the group treated with maitake alone,
respectively (Figure 2A). Figure 2B shown the pictures of abdominal
area indicating the breast tumour of each mouse from the beginning to
the end of treatment in each assayed condition.
Figure 2: Effect of maitake as coadyuvant with chemotherapy in
tumour grow size. A represents a graphics of tumour size average
(cm) after 1, 8, 15 and 22 days of treatment. Blue line represents the
chemotherapy treatment, red and green line represents the Maitake
Pro4X treatment with or without chemotherapy. B represents the
abdominal area of mice from every condition after 1, 8, 15 and 22
days after treatment. Red arrows indicate the location of mammary
tumour.
Effect of Maitake Pro4X and chemotherapy on tumour
necrosis
The in vivo macroscopic inspection of mammary tumours during
treatment showed that the tumours treated with Pro4X Maitake were
less aggressive and less ulcerative than those receiving chemotherapy
(Figure 3B). Mice treated with Maitake Pro4X alone exhibited
significantly less area of necrosis and ulceration (0.12 ± 0.20 cm2,
p<0.01) compared to those animals in the groups treated with
chemotherapy with or without Maitake Pro4X (0.85 ± 0.22 cm2 and
0.80 ± 0.20 cm2, respectively) (Figures 3A and 3B).
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Figure 3: Effect of maitake on tumour necrosis. A shows the graphic
of tumor necrosis area (cm2) after 22 days of treatment with or
without maitake and chemotherapy. In the graphic, n.s means
statistically none significant and *p<0.05. Below, pictures represent
the tumoral necrosis area from every representative mouse at each
condition (B).
Effect of Maitake Pro4X and chemotherapy on mortality
Mortality was higher in the animals treated with chemotherapy
alone, and achieves an average of 40 ± 6.0% (Figure 4A), whereas in
the groups treated with maitake alone or in combination with
chemotherapy, mortality was significantly lower (15 ± 3.0%, and 10 ±
2.0%, respectively with p<0.001) (Figure 4A). It was interesting to note
that 40% of the animals died because chemotherapy treatment after
one week (Day 8, indicated with blank squares, Figure 4B), then
mortality increase at 60% until the end of experiment. In the animals
treated with combination of chemotherapy and Maitake Pro4X, we
observed that mortality achieved up to 40% at the end of treatment
(Figures 4A and 4B). However, a significant reduction (p<0.001) were
observed in the number of dead animals in the group treated with
Maitake Pro4X alone (Figures 4A and 4B). Only two animals died at
the end of treatment (10 ± 2.0%, with p<0.001) in the group treated
with Maitake Pro4X (Figure 4B).
Figure 4: Effect on mortality after breast tumor treatment. Total
mortality (%) were measured after the end of treatment at any
condition indicated in A. ** means p<0.01. the graphic below (B)
represents the abdominal mice pictures at each condition after 1, 8,
15 and 22 after treatment.
Effect of Maitake Pro4X and chemotherapy on relative
survival
In order to determine whether the tumor treatment with Maitake
Pro4X could improve mice relative survival, we determined the
number of mice remaining alive after treatment. Figure 5 show the
results at different times during the treatment; until day 21st of
treatment, relative survival curve was similar in Maitake Pro4X groups
with or without chemotherapy (1.0 ± 0.00, and 1.0 ± 0.0 respectively),
none deaths was registered in any group. Relative survival was lower in
the chemotherapy group, since the first week (Day 8) were reduced
until 40% (Figure 5); at day 15th of treatment was even lower and at
the end of the experiment was cero (0.00%), none of the animal were
alive (Figure 5). The rate of relative survival in the combined treatment
with Chemotherapy+Maitake Pro4X was reduced up to 40% at day
23rd after treatment and then were also null 0.00% at the end of
experiment because all the mice died. Is clear to note the treatment
with Maitake Pro4X (5 mg/kg) improved the relative mice survival,
achieving up to 40% until de end of the experiment (Figure 5).
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Figure 5: Overall survival percentage curve after breast tumour
treatment. The graphic shows the percentage of overall survival of
female BALBc mouse after chemotherapy treatment alone, in
combination with Maitake Pro4X or Maitake Pro4x alone over 8 to
26 days of treatment. Overall survival indicates the number of mice
that remained alive at the end of treatment (at 26 days) with respect
to the total number of mice studied in each group. At each arrow
time indication, *means p<0.01.
In vitro effect of Maitake Pro4X on cell death
Tumour cell death values depending on the concentration of
Maitake Pro4X Fraction D at 24, 48 and 72 hours of treatment are
shown in Figure 6A, showing that the percentage of cell death were
significantly increased depending on both the concentration of
Maitake Pro4X and the duration of treatment. The highest percentage
of cell death (61.52 ± 0.89%) corresponded to treatment with the
highest dose of Maitake (734 µg/ml) for 72 hours, the longest
treatment duration (Figure 6A). It is important to clarify here that, the
734 µg/ml of Maitake Pro4X employed in the cell cultured medium is
equivalent to 5 mg/Kg in the animal treatment.
In vitro effect of chemotherapy with cyclophosphamide and
doxorubicin on cell death
Figure 6B displays a graph of tumour cell death values plotted
according to the concentration of the chemotherapeutic drugs used
(doxorubicin and cyclophosphamide) for 24, 48 and 72 hours. Figure
6B shows the cell death percentage at increased concentrations of the
chemotherapeutic drugs. In all treatments (except in the lower dose),
cell death was significantly higher (Student’s t-test. P ≤ 0.05) relative to
controls. We also found that the highest percentage of cell death (80.75
± 2.66%) corresponded to the higher concentration of chemotherapy
used (40 µM doxorubicin+2.5 µM cyclophosphamide). The optimal
time of cytolytic action was also the longer treatment (72 hours)
(Figure 6B).
In order to compare the effect of both Chemotherapy and Maitake
on cell death at each concentration during 24 hours, 48 and 72 hours,
Figure 6C were made. From those graphics were observed not
significant differences in cell death at 24, 48 or 72 hours between
treatments at any concentration, except the highest dose used with
chemotherapy that showed to be significantly different (p<0.05) with
respect Maitake treatment at 24 and 48 hours, not at 72 hours.
Figure 6: Dose-dependent LM3 cell death curves at 24, 48 and 72
hours after treatment. A: This figure shows the % of tumour LM3
cells death after dose-dependent treatment with Maitake Pro4X
after 24 hours (blue line), 48 hours (red line) and 72 hours (green
line). B: This figure shows the tumour LM3 cells death % after dose-
dependent treatment with chemotherapy after 24 hours (green
line), 48 hours (blue line) and 72 hours (orange line). C: the
graphics represents the effect on cell death at the comparative
treatment of Maitake and Chemotherapy after 24 hours (upper
graph), 48 hours (Middle graph) and 72 hours (bottom graph) of
treatment. In the graphs, blue columns represent the Maitake Pro4X
treatment and red columns represent the chemotherapy treatment
at any increased dose.
In vitro effect of Maitake D-fraction on normal human breast
cells MCF-10F
In order to demonstrate if Maitake D-fraction Pro4X has selectivity
on cell death in tumor cells but not in normal breast cells, we measured
the number of deaths MCF-10F cells after treatment at increase doses
and at different times. Cells were incubated by triplicate with D-
Fraction at 37°C in controlled atmosphere with 5% CO2 in serum free
medium. At the end of treatment, cell deaths were determined by the
technique of Trypan Blue exclusion assay, counting percentage of dead
and percentage of live cells in Neubauer chamber. The assay was tested
at increase concentrations of Maitake D-Fraction at 91, 183 and 367
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ug/ml of culture medium during 24, 48 and 72 hours. All the
experiments were done by triplicate. Surprisingly, treatment of cells
normal mammary MCF-10F cells, with increased concentrations of D-
fraction did not caused significant increases in the percentage of cell
death compared to control at any experimental dose (Figure 7).
Figure 7: Cell death caused by different concentrations of Maitake
D-fraction on MCF-10F cells at 24, 48 and 72 hours of treatment.
This figure shows the percentage of normal or non-malignant
MCF-10F cells death after dose-dependent treatment with Maitake
Pro4X after 24 hours (blue line), 48 hours (red line) and 72 hours
(green line). Cell death was measured with method of Trypan Blue
exclusion dye as indicated in methodology. The values represented
the mean ± correspond to S.D. (n=3). In the figures, n.s means no
significant differences were found with respect to control.
Discussion
Excessive tumour cell proliferation, an essential tumour process, is
due to deregulation of cell growth. Because of the acquisition of
mutations by cells, certain genes involved in the regulation of cell
proliferation or differentiation become oncogenes that trigger
tumorigenesis and developed cancer. Cells undergo uncontrolled
proliferation and escape apoptosis, either via physiological pathways
that induce apoptosis or by the inactivation of inhibitory pathways.
The disruption of apoptosis can also contribute to the development of
metastasis because it allows some tumour cells to survive in the
bloodstream and to invade other tissues, allowing cells in suspension
to evade apoptosis [32]. Therefore, finding compounds that cause
apoptosis in tumour cells specifically is of particular interest. Many
chemotherapy drugs act by inducing apoptosis in these cells but lack
specificity and thus affect nearly all actively dividing cells. As
mentioned previously, the antitumor properties of the Maitake D-
Fraction are attributed to its immunomodulatory effect. Reports have
also indicated that Maitake directly induce apoptosis in tumour cells
such as prostate [33], stomach [34], kidney [35] and breast [36] cancer
cells.
In this work, were studied the effects of the Maitake D-Fraction and
chemotherapy (cyclophosphamid+doxorubicin) on cell death in
murine breast cancer LM3 cells. Different concentrations of Maitake
Pro4X alone or in combination with chemotherapy at different times
were employed to study the effect on tumour cells in culture. The
results show that both, Maitake and chemotherapy treatments,
increased tumour cell death in a concentration- and time-dependent
manner. Thus, the Maitake D-fraction treatment alone may have a
chemotherapeutic effect by inducing cell death in a dose-dependent
manner. In previous studies, we demonstrated that tumour MCF-7 cell
death was induced by Maitake Pro4X via apoptosis [36]. Moreover,
were observed that treatment with chemotherapeutic drugs increased
cell death at a higher level compared with treatment with the Maitake
D-fraction.
By another hand, we also demonstrate that the effect on cell death
induced by Maitake was specific to breast tumour cells because not
significant death was detected in the experiment employing normal
breast MCF-10F cells.
Despite advances in the treatment of breast cancer, many obstacles
remain unsolved. In many cases, the conventional treatment was
ineffective due to resistance of the tumour to treatment or due to
metastases. Moreover, existing therapies can produce adverse effects
due to their specificity. For these reasons, finding a new treatment
regimen, which helps patients to better tolerate while treating the
cancer, inhibiting metastasis, increasing survival and improving
patient quality of life is needed.
Thus, in this work was studied the effect of orally administered
Maitake D-fraction in mammary tumourigenesis in BALBc mice. As
chemotherapy, Maitake Pro4X alone or in combination with
chemotherapy treatment did not significantly reduce the tumour size
(cm) in BALBc mice. By contrast with our results, Hishida et al. [22],
has been reported a 64% inhibition of tumour growth in C3H/HeN
with breast carcinoma mice that were orally administered with 3.0
mg/ml D-Fraction (directly extracted from the Maitake fruiting body).
However, in the present work, a commercial product of Maitake D-
Fraction Pro4X was used. Moreover, the orally administered
chemotherapy at a dose of 4 mg/kg of doxorubicin and 80 mg/kg of
cyclophosphamide did not reduce the tumour size either. These results
are in contrast with Ottewell et al. [37], who inoculated nude MF1
mice with human MDA-MB-436 breast cancer cells. After 7 days of
weekly-administered doxorubicin (2 mg/kg by intravenous injection, a
classical method of chemotherapy administration), they evaluated
tumour growth; significant differences were observed in the tumour
volume of animals receiving doxorubicin compared with that of
control animals. Another study from Riwanto et al. [38] found a
reduction of tumour growth in C3H mice that were inoculated with
breast cancer cells and that were treated intravenously with 0.013 mg
of cyclophosphamide plus 0.0156 mg of doxorubicin. Here is necessary
to talk about why not differences were found in the reduction of the
tumour volume after treatment of chemotherapy alone or in
combination with Maitake D-Fraction Pro4X. Not differences were
found in the breast-tumour volume from BALBc mice treated with
Maitake alone, either. These results are support by our recent findings
[39], whether no significant reduction in the breast tumour volume
were found after oral treatment during cancer prevention with Maitake
Pro4X (5 mg/kg) of BALBc mice compare to the control untreated.
However, histological studies of those breast tumours revealed that
Maitake Pro4X treatment reduce the malignancy of the tumour,
acquiring benign characteristics, such as be full of liquid inside, with
net borders and with a small mitotic index. In contrast the breast
tumour from the control group that have the characteristic of tumour
malignancy with irregular borders, solid aspect and high mitotic index.
By another hand, higher mortality in the group of mice treated with
chemotherapy alone was found. However, the combination of
chemotherapy with Maitake Pro4X prevented death from toxicity
caused by chemotherapy itself. Furthermore, mortality was
significantly lower in the group treated with Maitake Pro4X alone. This
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can be explained by considering the adverse effects of treatment with
cyclophosphamide and doxorubicin [9,15,16]. In agreement with those
results, Baselga et al. [40] reported that mortality was higher (21%
compared with 13% in the control animals) in athymic BALBc mice
treated with intraperitoneal injections of doxorubicin (100 mg/20 g
body weight) after 15 days of treatment. Thus, the rate of mortality
induced by doxorubicin was high [40].
Conclusion
In this work, we demonstrated that treatment with Maitake D-
fraction stimulates cell death in LM3 tumour cells in culture.
Furthermore, these results suggest that the administration of Maitake
D-fraction Pro4X alone or in combination with chemotherapy
increases the overall survival of mice with breast tumours.
Interestingly, although it could protect against the adverse effects of
chemotherapy, such as reduce mortality, increase the overall survival,
and reduce tumour necrosis and malignancy. The beneficial effects of
Maitake Pro4X could be useful for the treatment of cancer patients
receiving chemotherapy or radiation.
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